DY
RNAM

Dowling & Yahnke’s Avidity Biosciences RNAM Stock Holding History

Dowling & Yahnke’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$175K Sell
10,691
-590
-5% -$11.3K 0.01% 355
2022
Q2 		$164K Hold
11,281
– – 0.01% 359
2022
Q1 		$208K Hold
11,281
– – 0.01% 357
2021
Q4 		$268K Hold
11,281
– – 0.01% 332
2021
Q3 		$278K Sell
11,281
-2,460
-18% -$53.5K 0.02% 317
2021
Q2 		$340K Hold
13,741
– – 0.02% 295
2021
Q1 		$300K Buy
+13,741
New +$336K 0.02% 292

Other funds holding RNAM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Dowling & Yahnke's RNAM Position: Q3 2022 in Review

Dowling & Yahnke reduced its Avidity Biosciences (RNAM) stake by 5.2% in Q3 2022, selling an estimated $11.3K and leaving 10,691 shares worth $175K. The position accounts for 0.01% of the portfolio, ranked #355.

Dowling & Yahnke first reported a position in RNAM in Q1 2021 and has held it in 7 quarters since. The position peaked at $340K in Q2 2021. 127 funds tracked by Wall St. Rank hold RNAM as of Q3 2022.

  • Dowling & Yahnke held 10,691 shares of Avidity Biosciences worth $175K as of Q3 2022.
  • Dowling & Yahnke sold 590 Avidity Biosciences shares in Q3 2022, an estimated $11.3K.
  • Avidity Biosciences made up 0.01% of Dowling & Yahnke's portfolio in Q3 2022, its #355 holding.
  • Dowling & Yahnke first reported a position in Avidity Biosciences in Q1 2021 and has held it in 7 quarters since.
  • Dowling & Yahnke's Avidity Biosciences position peaked at $340K in Q2 2021.
  • 127 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2022.

Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.